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ABSTRACT
A national survey has been conducted to assess the
transparency in public pharmaceutical sector in Indonesia. The
survey was conducted during 2007, and writer was appointed
by the government as independent assessor. The assessment
covered five functions of government in pharmaceutical sector,
i.e., registration, control of promotion, inspection of production,
selection of essential medicines, and central procurement of
national buffer stock. Key informants were selected based on
first-hand knowledge on each function, representing
government, pharmaceutical company, academe/professionals,
and NGOs, i.e. 10 informants for each registration, control of
promotion, inspection of production, selection of essential
medicines, and 20 informants for central procurement. Data
were collected by means of in-depth interviews, using sets of
questionnaires provided by the WHO. Findings were analyzed
following a scoring system that ranging from zero to ten. The
smaller the score indicates in-transparency, and therefore
indicates the more vulnerability for corruption.
The results showed that the registration process scored 7.2,
control of promotion scored 7.6, inspection of production scored
8.7, selection of essential medicines scored only 5.5, and the
central procurement scored 7.0. In general, it is appreciated
that the functions of registration, control of promotion,
inspection, and procurement were well governed, but the
selection of essential medicines obtained a low score. There
has been remarkable lacking of written procedures that publicly
available. In regard to the selection function, there is no written
procedure in every process of selection, i.e., selection criteria
of the revision committee member, written criteria for application,
written criteria for addition, substitution and deletion, and written
procedures of decision making. Declaration of interest is to
some extents, lacking from most functions. It was
recommended that the Government should establish written
procedures of each function and make them publicly available,
establish mechanism to minimize conflict of interest in each
function i.e., by means of declaration of interest, and establish
measures to fill up regulatory gaps. By the time of publication,
corrective actions in all five functions have been made and at
the time being the Government is ready for re-assessment.
Key words: transparency, pharmaceuticals, good governance,
public sector, vulnerability for corruption
ABSTRAK
Suatu survey nasional telah dilakukan untuk menilai transparansi
di sektor public pelayanan obat di Indonesia. Survei dilakukan
tahun 2007, dan peneliti bertindak sebagai assessor independen
yang ditunjuk pemerintah. Penilaian dilakukan terhadap lima
fungsi pemerintah di sektor obat, yaitu registrasi, pengendalian
promosi, inspeksi produksi, seleksi obat esensial, dan
pengadaan obat di tingkat pusat. Informan kunci dipilih
berdasarkan penguasaan masalah yang terkait dalam setiap
fungsi, mewakili pemerintah, produsen obat, institusi pendidikan
dan profesi, dan lembaga masyarakat, meliputi masing-masing
sepuluh informan untuk fungsi registrasi, pengendalian
promosi, inspeksi produksi, seleksi obat esensial, dan 20
informan untuk fungsi pengadaan obat. Data dikumpulkan melalui
wawancara mendalam dengan menggunakan pedoman
interview yang telah dikembangkan oleh WHO. Informasi yang
diperoleh dianalisis dan diberi nilai antara 0-10. Nilai kecil
menunjukkan kecilnya transparansi, yang dapat menunjukkan
besarnya kerawanan untuk terjadi korupsi.
Hasil penelitian menunjukkan bahwa fungsi registrasi mendapat
nilai 7,2, pengendalian promosi 7,6, inspeksi produksi 8,7,
seleksi obat esensial 5,5, dan pengadaan obat di tingkat pusat
mendapat nilai 7,0. Secara umum dapat disimpulkan bahwa
tatakelola untuk ke empat fungsi pemerintah relatif sangat baik,
sedangkan nilai yang diperoleh untuk fungsi seleksi obat
esensial kurang baik. Kelemahan utama di semua fungsi adalah
tak tersedianya informasi tertulis tentang prosedur tatakelola
yang dapat diakses publik. Rendahnya nilai untuk seleksi obat
esensial disebabkan tidak adanya prosedur tertulis pada setiap
langkah tatakelolanya, misalnya prosedur pemilihan anggota
tim seleksi, kriteria pendaftaran, penambahan, penggantian atau
penghapusan obat dari daftar obat esensial, dan prosedur
tertulis untuk membuat keputusan. Belum dilembagakannya
deklarasi kepentingan juga merupakan kelemahan di berbagai
fungsi tatakelola obat. Kepada pemerintah telah disarankan
untuk memastikan bahwa prosedur tertulis untuk setiap fungsi
tatakelola tersedia di ranah publik, mengelola konflik kepentingan
dengan lebih baik di setiap fungsi, dan menutup kesenjangan
regulasi bila ada. Pada waktu hasil penelitian ini dipublikasi,
berbagai langkah perbaikan telah dilakukan di kelima fungsi
dan pemerintah menyatakan siap untuk di nilai ulang.
Kata kunci:
transparansi, obat, tatakelola pemerintahan yang baik, sektor
publik, kerawanan untuk korupsi
BACKGROUND
Registration of medicines is a crucial government
function that ensures the quality, efficacy, and safety
standards of registered medicines in the country.1
It’s also one of the most important barriers to entry
the pharmaceutical market. However, registration
should be followed with adequate inspection of the
production. Without control of pharmaceutical
promotion, availability of pharmaceuticals will only
end up with inappropriate use of medicines. Therefore,
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it is important that the regulation of pharmaceuticals,
including registration, inspection of production, and
promotion is transparent. In Indonesia, the National
Agency for Drugs and Food is responsible for these
three functions.
Besides the regulation function, selection of
medicines also requires government to make
decisions about what medicines are to be included
in the National Essential Medicine List. The selection
of medicines to be included in the List may be
vulnerable to conflicts of interest if the process is
not transparent. Another crucial function is
procurement of medicines. Procurement not only
requires accurate purchase quantification, but must
also ensure that the right medicines are procured to
meet the needs of the population. Transparency in
procurement process is therefore a must, i.e., by
following formal written procedures throughout the
process and using explicit criteria to award contracts.
In Indonesia, these two functions are among the
responsibility of the Directorate General of
Pharmaceutical Services of the Ministry of Health.
Promoting ethical practices in pharmaceutical
sector is a part of the WHO Global Medicines
Strategy 2004-2007.2 The World Health Organization
(WHO) provides technical and financial supports to
countries which are willing to conduct activities to
assess, and furthermore to improve transparency in
the five government functions of pharmaceutical
sector. Serial workshops have been conducted,
guideline for assessment has been provided.
Assessments of government function in
pharmaceutical sector have been done in many
countries, including Cambodia, Lao PDR, Malaysia,
Mongolia, Papua New Guinea, Philippines, and
Thailand,3 and many more countries in East
Mediterranean and African Regions4 later joined the
movement and work together in strengthening
technical components in improving good governance
in pharmaceuticals.
Objectives of the study
The objectives of the study were to identify the
level of transparency in the five functions of
pharmaceutical sector in Indonesia, i.e., registration,
promotion, inspection, selection of essential
medicines, and procurement of medicines. Results
of this assessment were communicated to the
Government for further use.
Methods
A national survey was conducted following the
method recommended by World Health
Organization.5 Key informants were selected based
on their first-hand knowledge about the subject and/
or their level of involvement in the pharmaceutical
sector, representing government, pharmaceutical
company, academe/professionals, and NGOs. The
writer initially set the characteristics of each group
of respondents and discussed them with the
Government. Then the Government identified name(s)
of potential candidate(s). When several names were
identified, the writer randomly selected ones. The
final number of the selected key informants included
10 for registration, 10 for control of promotion, 10 for
inspection, 10 for selection issue, and 20 for
procurement.
After the decentralization of pharmaceutical
procurement in public sector, the national government
is responsible for national buffer stock, social security
for poor people (JPKM-Miskin), and drug procurement
for vertical programs. Based on its biggest value of
procurement compared to the others and considering
its nation-wide distribution, the procurement of
national buffer stock was selected as the object of
the assessment.
Data were collected by in-depth interview.
Indepth interviews were conducted by the writer and
trained interviewers. The WHO interview guides were
translated into Bahasa Indonesia and refined for easy
use by interviewers. The translation version of the
guides was pilot-tested before use. Interviews were
noted and recorded, and verbatim of each interview
was produced for further analysis.
Based on the notes and verbatim of each
respondent, qualitative information of each score was
processed by means of content analysis. Important
points were tabulated according to the number of
questions and translated back into English. Then
the writer scored/rated them following the WHO
method, as described below. Scores and qualitative
findings were then triangulated
The WHO5 suggests four types of indicators to
determine the level of transparency. The first type of
indicators required a binary answer (yes/no), aimed
to minimize subjective for interpretation of the
findings. interpretation of key informants’ responses.
The second type included a series of sub-questions
or criteria that also require a binary answer.
For these two types of questions, a “yes” is
given a value of one (1) and a “no” is given a value of
zero (0). A value of one represents low vulnerability
to corruption. A rating of zero represents potential
vulnerability to corruption since the absence of a
standardized process or decision criteria provides
decision makers with broad discretion in their
decision making. Information collected was validated
with existing evidence. Even though informants
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indicated that documents existed in the country,
documents were classified as non existent if the
writer was unable to access them, because it
showed a lack of transparency in some procedures.
Once all the interviews were completed and all
indicators rated according to the criteria, an average
score was calculated for each function and converted
to a zero to 10 (0.0 to 10.0) scale to represent different
degrees of vulnerability to corruption (Table 1).
Table 1. Ten-point rating scale as developed by WHO5
Extremely 
Vulnerable  
Moderately 
vulnerable 
Marginally 
vulnerable 
Minimally 
vulnerable 
0.0 – 2.0 
Very 
vulnerable
2.1 – 4.0 4.1 – 6.0 6.1 – 8.0 8.1 – 10.0 
The third type of questions involves subjective
questions that probe the perceptions of the key
informants. Informants were asked whether they
strongly agreed, agreed, were undecided, disagreed,
or strongly disagreed with a number of statements.
Basic frequencies were used to present the results.
The fourth type used open questions, allowing key
informants to provide additional input on the function
in general. This paper presents only on the first two
types of data.
Results and discussions
Ten key informants were recruited for registration
process, ten for control of promotion, ten for the
inspection of production, ten for the selection of
essential medicines, and 20 for the central
procurement. The background of the key informants
was described in Table 2, covering informants from
the Government (central, provincial or district),
pharmaceutical industry, academe/professionals,
and non-governmental organizations.
Table 3 describes the summary results of the
assessment. High scores were obtained in
registration (7.2), control of promotion (7.6),
inspection of production (8.7), and central
procurement (7.0). Unfortunately, the score obtained
from the assessment of selection of essential
medicines is low (5.5).
Details, as well as strengths and weaknesses
of each function are described in Table 4 to 8. Those
tables describe the scores of each question.
Attention should be paid to questions that are scored
low (i.e. less than 7.0), as these reflect weaknesses
in governing the functions. In other words, questions
with low scores indicate the components that need
to be established or strengthened, in order to improve
good governance in public pharmaceutical sector.
Registration
The registration process scored 7.2; and details
are described in Table 4. From the answers to
Question 1, it seems that the access to the updated
list of registered pharmaceutical products was limited
only to pharmaceutical company, although the list
was available on the web (http://www.bpom.go.id)
and in the registration area of the National Agency
of Drug and Food Control, Building D, Jakarta.
Responses to Question 2 confirmed however, that
although updated list was available the information
was very little.
Responses to Questions 3, 4, 5, 6, 7 confirmed
that national guideline for new drug registration was
publicly available, clear and comprehensive, as
evidenced by the National Guideline which is publicly
available.6 All respondents except NGO were positive
that the registration process was transparent and
did not allow collusions, because it applied collective
scientific decision process and involved independent
Table 2. Background of key informants
Group of key informants N Government 
 
Private/ 
pharm. industry 
Academe/ 
professionals 
NGO 
Registration 10 4 central 4 1 1 
Control of promotion 10 4 central 4 1 1 
Inspection 10 4 central 4 1 1 
Selection of essential medicines 10 4 central 2 2 2 
Central procurement 20 4 central 
2 provincial 
6 district 
3 3 2 
Table 3. Summary table of the results of transparency assessment on
registration, control of promotion, inspection, selection, and procurement
No Function Score Vulnerability 
1 Registration 7.2 Marginal 
2 Control of promotion 7.6 Marginal 
3 Inspection of production 8.7 Minimal 
4 Selection of essential medicines 5.5 Moderate 
5 Central procurement of national buffer stock 7.0 Marginal 
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experts with high integrity. Unfortunately, the criteria
for selecting the committee members and the
composition of the committee are not known by the
public. To this issue, the government respondents
explained that the composition is kept disclosed from
the public in order to avoid communication between
members and drug applicants prior to decision
making.
In the other hand, responses to Questions 8, 9,
10, and 12 indicated that both government and
industry respondents expressed that some important
measures to ensure transparency in the future were
lacking, i.e., written criteria for members of drug
evaluation committee, written declaration of  interest
by members of the drug evaluation committee and
the written procedure of decision making.
Control of promotion
The control of promotion scored 7.6, and details
are described in Table 5. Responses to Questions
17, 19, and 20 showed that all respondents able to
explain Laws, Decrees, and regulations that control
promotion and protect consumers. Evidence shows
that the WHO Guideline on Ethical Criteria for
Medicinal Drug Promotion7 is well implemented in
the National Regulations. In addition, respondents
from industry underlined IFPMA codes8 that had been
adopted by Indonesian Association. Industry
respondents were positive that the control of
promotion was well–respected while government
respondents expressed their worries that the
regulation was not well-respected by industry.
All respondents agreed that control of
promotions had involved all relevant stake holders.
However, responses to Question 21 and 22 expressed
that most respondents concerned that
implementation of the sanctions was inadequate and
inconsistent.
Inspection of production
Inspection of manufacturers scored 8.7 and
details are described in Table 6. Questions 29, 30,
31, 32, 35, and 36 scored very high. Key informants
from both industry and government recognized the
Table 4. Results of assessment on registration process
Question No. Description Score (n=10) 
1 Is there an up-to-date list of all registered pharmaceutical products available in the 
country? 
5.6 
2 If such a list exists, does it provide a minimum level of information? 5.1 
3 Are there written procedures for applicants on how to submit an application for 
registration of medicinal products?  
8.9 
4 Are there written procedures for assessor s on how to assess applications submitted 
for registration of medicinal products?  
7.5 
5 Is there a publicly available and standard application form for submission of 
applications for registration of medicinal products? 
9.5 
6 Are there written guidelines  setting limits on how and where medicines registration 
officers meet with applicants?  
6.3 
7 Is there a functioning formal committee responsible for assessing applications for 
registration of pharmaceutical products? 
10.0 
8 Are there clear written criteria for selecting the members of the committee? 5.7 
9 Is there a written document that describes the composition of the committee? 4.8 
10 Is there a conflict of interest (COI) form that members of the committee and public 
officials are obliged to complete? 
7.5 
12 Is there clear and comprehensive guidance for the committee's decision-making 
process? 
5.1 
13 Is there a formal appeals system for applicants that have their drug applications 
rejected? 
10.0 
Average score 7.2 
Table 5. Results of assessment on control of promotion
Question No. Description Score (n=10) 
17 Is there a provision in the medicines legislation/regulations covering drug 
promotion and advertising? 
10.0 
19 Are the provisions on drug promotion and advertising comprehensive?  8.3 
20 Do the provisions foresee an enforcement mechanism on promotion and 
advertisement of medicines?  
8.5 
21 Is there a service or committee responsible for monitoring and enforcing the 
provisions on drug promotion?   
5.4 
22 Are there written and publicly available Standard Operating Procedures (SOPs) 
guiding the services responsible for pre-approving or monitoring drug promotion 
and advertising? 
5.8 
Average score 7.6 
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Indonesian Good Manufacturing Practices (GMP)9
and Good Distribution Practices (GDP)10 as the
national guidelines. In addition, key informants from
industry also mentioned their Company’s SOP for
inspection. Industry and government respondents
agreed that the national GMP and GDP were clear,
detailed, and strict enough to ensure the transparent
process of inspections.
However, responses to Questions 33 showed
that both sides were aware that there was no
“Declaration of Interest” as like the WHO form. Some
informants mentioned that there was “Inspector’s
Oath”. An NGO respondent expressed worries of the
selection of inspectors as it was a high qualified
position and she was not sure whether there were
enough candidates to be recruited as inspectors.
This issue was confirmed by the Government
respondents, and they agree that more competent
inspectors should be prepared in the near future.
Selection of essential medicines
Selection of essential medicines scored 5.5;
details are depicted in Table 7. All key informants
mentioned that the National Essential Medicine List
(NEML) was frequently updated, the last update was
in 2005,11 and was available for health managers.
Government informants confirmed that the revision
procedure followed the WHO guidelines.12
All informants acknowledged that the
Committee of NEML Revision consisted of well-
respected people with high credibility and integrity.
Unfortunately, most of the procedures were not
written or not available to public. Non-government
informants said that the selection process had
involved experts with high integrity, but they did not
know if there were criteria for being committee
members. Government respondents were aware that
the most important measures to ensure transparency
were lacking, i.e., written criteria for members of
selection committee, written declaration of  interest
by members of the selection committee and the
written procedure of revision that publicly available.
On the other hand, the writer noted a strong evidence
of high quality of National Medicine List,11 meaning
that the good works relied on the good people. For
sustainability, however, written procedures and more
appropriate management of conflict of interest should
have been in place.
The result of this study was directly
communicated with the Chair of the Committee of
NEML Revision, which was by coincidence in the
preparation of the 2008 revision of the List. Corrective
Table 6. Results of assessment on inspection of production
Question No. Description Score (n=10) 
29 Is there a provision in the medicines legislation/regulation covering inspection of 
medicines manufacturers and distributors? 
10.0 
30 Is the provision comprehensive enough?  10.0 
31 Are there written guidelines on classification of Good Manufacturing Practices 
(GMP) or Good Distribution Practices (GDP) non-compliance that describe the 
types of deficiencies and the corresponding measures to be taken by the MRA? 
9.0 
32 Are there written procedures/mechanisms to prevent capture between an 
inspector and the manufacturers or distributors that he/she inspects? 
7.3 
33 Are there written comprehensive guide lines detailing the situations regarded as 
conflict of interest (COI) with regard to inspection activities? 
4.8 
34 Are inspection findings and conclusions subject to an internal review? 8.9 
35 Are there written procedures for inspectors on how to conduct inspections?  9.6 
36 Are there written criteria for the selection and recruitment of inspectors? 10.0 
Average score 8.7 
Table 7. Results of assessment on selection of essential medicines
Question No. Description Score (n=7) 
40 Does the government have an officially adopted national essential medicines list 
publicly available? 
6.0 
42 Are there clearly written and transparent rules/criteria for the selection process 
for including or deleting medicines from the national EML? 
7.7 
43 Is the EML in line with WHO procedures? 8.7 
44 Is there a committee responsible for the selection of the national EML? 10.0 
46 Are there clear criteria for the selection of members of the selection committee? 5.7 
47 Is there a conflict of interest (COI) form that members of the selection committee 
are obliged to complete? 
0.0 
48 Are there clear and publicly available Standard Operating Procedures that 
describe the role and responsibilities of the selection committee? 
0.0 
49 Are the rules for decision-making in the SOP clear and transparent? 5.8 
Average score 5.5 
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actions had been made, and the Committee was
then in full compliance with the international
Guidelines and ensured its transparency and
accountability.
Central procurement
Central procurement of national buffer stock
scored 7.0; details are described in Table 8. All
informants were able to explain the Presidential
Decree No. 80 (enacted in 2003)13 as the national
regulation for transparent procurement. The evidence
shows that in majority, the Decree is concordance
with the international guideline.14 The majority of
informants expressed that the Presidential Decree
was comprehensive, clear, and strict enough to
ensure transparent procurement. These opinions
were indicated by their responses to Questions 52,
53, 54, 55, and 56.
Responses to Questions 58, 60, 61, 62, and 63
however, indicated that some informants raised the
issue that there was no declaration of interest of the
Tender Committee members. Respondents from
district level expressed concerns that procurement
procedure for medical devices was not as strict as
medicines and therefore provided rooms for deviation.
All government informants mentioned that integrated
post-tender management information system was
lacking. Monitoring was usually conducted manually
and it usually took a long time to follow up complaints.
Strengths and weaknesses of the assessment
method
The writer found the WHO questionnaires were
easy to use. Questions were very detailed showing
what everything should be. While conducting the
survey, the questionnaires themselves pointed out
every strength and weakness of the system. In short
the assessment tool can be used as an educational
tool; as we survey we teach. The writer also found
that the questions attracted key informants to explain
lots of things when they knew the situation, or if
they had complaints to related topics. Although all
interviews were recorded, to make data collection
much easier the writer recommended the
questionnaires are developed into data collection
booklets, providing enough rooms to write down
information for each sub-question. For further
analysis, the writer also developed worksheets that
allowed her to compile summary of qualitative
information and provided step-by-step calculation of
scores. The step-by-step calculation allowed the
writer to re-check and cross-check the scores.
However, the writer found a question which is
contrary to the country’s regulations. The Indonesian
Presidential Decree No. 8013 clearly stated that
involvement of senior government officials in the
Tender Committee is prohibited because they were
considered as funding users, and therefore their
involvement in tender committee conflicted with their
interests. However, the WHO questionnaire supports
their involvements in tender committee. Some short-
coming were identified, e.g., the number of indicators
was not balanced as in promotion with only 5 scored
indicators, as compared to twelve in registration, eight
in inspection, eight in selection of essential
medicines, and 11 in procurement. There was also
inconsistency due to as some questions requiring
proof of written documents, while others do not
(Questions 30, 35, 36, 61).
Conclusions and recommendations
Table 8. Results of assessment on central procurement of national buffer stock
Question No. Description Score (n=10) 
52 Does the government use transparent procedures for procurement of 
pharmaceutical products?  
8.1 
53 Is there written guidance for procurement office staff on the type of procurement 
method to be used for different types of products? 
8.6 
54 Is procurement done with an objective quantification method to determine the 
quantity of pharmaceuticals to be purchased? 
8.6 
55 Is there a formal appeals process for applicants that have their bids rejected?  9.3 
56 Is there a tender committee? If so are the key functions of the procurement office 
and those of the tender committee clearly separated? 
9.8 
57 Are there specific criteria for tender committee membership? 6.0 
58 Is there a conflict of interest (COI) form that members of the tender committee 
are obliged to complete? 
3.2 
60 Is there a management information system used to report product problems in 
procurement? 
4.4 
61 Are there Standard Operating Procedures (SOPs) for routine inspection of 
consignments?  
6.7 
62 Is there an efficient post-tender system in place to monitor and report on 
suppliers' performance to the tender committee? 
5.6 
63 Does the procurement office undergo regular audits? 6.7 
Average score 7.0 
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It is appreciated that the functions of
registration, control of promotion, inspection, and
procurement are well governed. However, there has
been remarkable lacking of written procedures that
publicly available. The score obtained from selection
of essential medicines is quite low, mainly because
there is no written procedure in every process of
selection, i.e., selection criteria of the revision
committee member, written criteria for application,
written criteria for addition, substitution and deletion,
and written procedures of decision making.
Declaration of interest is to some extents, lacking
from most functions.
It was recommended that the Government
should establish written procedures of each function
and make them publicly available, establish
mechanism to minimize conflict of interest in each
function and establish measures to fill up regulatory
gaps. Feedbacks to respective authorities have been
given right after the completion of the study. By the
time of publication, corrective actions in all five
functions have been in place and at the time being
the Government express its readiness for re-assessment.
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